Esperion Therapeutics Inc (NASDAQ:ESPR) shares, rose in value on Wednesday, March 26, with the stock price down by -2.98% to the previous day’s close as strong demand from buyers drove the stock to $1.63.
Actively observing the price movement in the last trading, the stock closed the session at $1.68, falling within a range of $1.62 and $1.7. The value of beta (5-year monthly) was 1.042. Referring to stock’s 52-week performance, its high was $3.94, and the low was $1.47. On the whole, ESPR has fluctuated by -5.78% over the past month.
With the market capitalization of Esperion Therapeutics Inc currently standing at about $322.50 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-03.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ESPR’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the price of ESPR currently trading nearly 0.49% and -9.95% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 45.89, while the 7-day volatility ratio is showing 5.74% which for the 30-day chart, stands at 7.29%. Furthermore, Esperion Therapeutics Inc (ESPR)’s beta value is 0.81, and its average true range (ATR) is 0.11.
A comparison of Esperion Therapeutics Inc (ESPR) with its peers suggests the former has fared considerably weaker in the market. ESPR showed an intraday change of -2.98% in last session, and over the past year, it shrunk by -28.82%%.
Data on historical trading for Esperion Therapeutics Inc (NASDAQ:ESPR) indicates that the trading volumes over the past 10 days have averaged 4.56 and over the past 3 months, they’ve averaged 4.25 million. According to company’s latest data on outstanding shares, there are 195.85 million shares outstanding.
Nearly 1.76% of Esperion Therapeutics Inc’s shares belong to company insiders and institutional investors own 65.74% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 28.9 million shares as on 2025-03-14, resulting in a short ratio of 7.27. According to the data, the short interest in Esperion Therapeutics Inc (ESPR) stood at 1465.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 28.1 million. The stock has fallen by -25.91% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ESPR stock heading into the next quarter.
